4.5 Article

Mitochondrial DNA disorders: from pathogenic variants to preventing transmission

Journal

HUMAN MOLECULAR GENETICS
Volume 30, Issue R2, Pages R245-R253

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddab156

Keywords

-

Funding

  1. National Institute for Health Research [CL-2016-01-003]
  2. Wellcome [204709/Z/16/Z, 215888/Z/19/Z, 203105/Z/16/Z]
  3. United Kingdom National Institute for Health Research Biomedical Research Centre for Ageing and Age-Related Disease award
  4. Lily Foundation
  5. United Kingdom National Health Service
  6. Newcastle University Centre for Ageing and Vitality
  7. Biotechnology and Biological Sciences Research Council
  8. Medical Research Council [G016354/1]
  9. Wellcome Trust [204709/Z/16/Z, 215888/Z/19/Z, 203105/Z/16/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

Mitochondrial DNA disorders are recognized as a common cause of inherited metabolic disorders, with a dynamic and tissue-specific pattern that poses challenges to diagnosis and treatment. The complex genetic inheritance of these diseases and the difficulty in finding disease-modifying therapies remain key issues. Advances in techniques such as in vitro fertilization have improved reproductive options, yet further research and exploration are needed.
Mitochondrial DNA (mtDNA) disorders are recognized as one of the most common causes of inherited metabolic disorders. The mitochondrial genome occurs in multiple copies resulting in both homoplasmic and heteroplasmic pathogenic mtDNA variants. A biochemical defect arises when the pathogenic variant level reaches a threshold, which differs between variants. Moreover, variants can segregate, clonally expand, or be lost from cellular populations resulting in a dynamic and tissue-specific mosaic pattern of oxidative deficiency. MtDNA is maternally inherited but transmission patterns of heteroplasmic pathogenic variants are complex. During oogenesis, a mitochondrial bottleneck results in offspring with widely differing variant levels to their mother, whilst highly deleterious variants, such as deletions, are not transmitted. Complemented by a complex interplay between mitochondrial and nuclear genomes, these peculiar genetics produce marked phenotypic variation, posing challenges to the diagnosis and clinical management of patients. Novel therapeutic compounds and several genetic therapies are currently under investigation, but proven disease-modifying therapies remain elusive. Women who carry pathogenic mtDNA variants require bespoke genetic counselling to determine their reproductive options. Recent advances in in vitro fertilization techniques, have greatly improved reproductive choices, but are not without their challenges. Since the first pathogenic mtDNA variants were identified over 30 years ago, there has been remarkable progress in our understanding of these diseases. However, many questions remain unanswered and future studies are required to investigate the mechanisms of disease progression and to identify new disease-specific therapeutic targets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available